Acumen Pharmaceuticals
ABOS
57 hedge funds and large institutions have $106M invested in Acumen Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 7 reducing their positions, and 12 closing their positions.
257% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 7
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
10% more funds holding
Funds holding: 52 → 57 (+5)
3.77% more ownership
Funds ownership: 63.23% → 66.99% (+3.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
39% less capital invested
Capital invested by funds: $173M → $106M (-$66.9M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $78K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.05M |
| 2 |
BlackRock
New York
|
+$3.93M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.7M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$3.62M |
| 5 |
PA
Perceptive Advisors
New York
|
+$3.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$10.6M |
| 2 |
Janus Henderson Group
London,
|
-$4.24M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$4.07M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$672K |
| 5 |
HF
HRT Financial
New York
|
-$553K |
ABOS Hedge Fund Activity: Q1 2022 in Review
57 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q1 2022, worth a combined $106M — down 39% from $173M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ABOS positions and 12 closed out — a net gain of 5 holders — while 25 added to existing stakes and 7 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $5.05M. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $10.6M sold.
- 57 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q1 2022, up from 52 in Q4 2021.
- Funds reported $106M of Acumen Pharmaceuticals stock for Q1 2022, down 39% quarter-over-quarter.
- 17 funds opened new Acumen Pharmaceuticals positions in Q1 2022 and 12 closed out, a net change of +5 holders.
- The largest Acumen Pharmaceuticals buyer in Q1 2022 was Great Point Partners, an estimated $5.05M added.
- The largest Acumen Pharmaceuticals seller in Q1 2022 was Rock Springs Capital Management, an estimated $10.6M sold.
Based on aggregated 13F filings for Q1 2022.